Merck, F6755-100MG, Fibrinogen from rat plasma

Application
Fibrinogen has been used in studies of haemostatic therapy in surgical and massive trauma patients. These studies have shown that fibrinogen may prove to be more superior in stopping blood loss when compared to using fresh frozen plasma (FFP).
Fibrinogen from rat plasma has been used:
in the preparation of growth factor solutions
to apply on discontinuous SDS-polyacrylamide gels for the detection of IgG (immunoglobulins) type antibodies by immunoblot analysis
to mix with cell suspension to form a clot and retain the cells for avoiding its dispersion during transplantation

Biochem/physiol Actions
Acute phase protein that is part of the coagulation cascade of proteins.
Fibrinogen is an acute phase protein that is part of the coagulation cascade of proteins. The end result of the cascade is the production of thrombin that converts fibrinogen to fibrin. Thrombin rapidly proteolyses fibrinogen, releasing fibrinopeptide A. The loss of this small peptide is not sufficient to make the resulting fibrin molecule insoluble, but it tends to form complexes with adjacent fibrin and fibrinogen molecules. Thrombin then cleaves a second peptide, fibrinopeptide B, from fibrin and the fibrin monomers formed then polymerize spontaneously to form an insoluble gel. The polymerized fibrin is held together by noncovalent and electrostatic forces and stabilized by the transamidating enzyme, factor XIIIa, that is produced by the action of thrombin on factor XIII. The insoluble fibrin aggregates (clots) and aggregated platelets then block the damaged blood vessel and prevent further bleeding. The amount of fibrinogen in the plasma can serve as a nonspecific indicator of whether or not an inflammatory process is present in the body. Fibrinogen from any mammalian source will be cleaved by thrombin from any mammalian source.
Analysis Note
Contains ~12% sodium citrate and ~18% sodium chloride.
Protein determined by biuret.